Skip to content

Shattuck Labs, Inc. STTK Business Segments — Research and development non-equity compensation

Similar metrics at other companies

Arcutis Biotherapeutics, Inc. logo
ARQTReportable Segment — Research and development compensation and personnel-related expenses
$11.05M+14.6%
Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Research And Development Expense, Personnel
$8.53M-8.6%
Bicara Therapeutics logo
BCAXReportable Segment — Research and development personnel cost and other (including stock-based compensation)
$9.12M+79.0%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Research And Development Stock Based Compensation
$19.33M+63.5%
Mirum Pharmaceuticals, Inc. logo
MIRMReportable Segment — Research and development expenses (excluding stock-based compensation)
$73.72M+106%
Apogee Therapeutics, Inc. logo
APGEReportable Segment Aggregation Before Other Operating — Research And Development Personnel Related Excluding Equity Based Compensation
$18.54M+21.2%

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept sttk:ResearchAndDevelopmentNonEquityCompensation.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s business segments — research and development non-equity compensation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s business segments — research and development non-equity compensation?
Shattuck Labs, Inc. (STTK) reported business segments — research and development non-equity compensation of $2.38M in Q1 2026.
How has Shattuck Labs, Inc.'s business segments — research and development non-equity compensation changed year-over-year?
Shattuck Labs, Inc.'s business segments — research and development non-equity compensation decreased by 0.6% year-over-year, from $2.4M to $2.38M.
What is the long-term trend for Shattuck Labs, Inc.'s business segments — research and development non-equity compensation?
Over 2 years (2023 to 2025), Shattuck Labs, Inc.'s business segments — research and development non-equity compensation has grown at a -28.5% compound annual growth rate (CAGR), from $17.85M to $9.13M.
What does business segments — research and development non-equity compensation mean?
Captures the cash-based salary, bonuses, and benefits paid to personnel directly involved in research and development activities within the reportable segment. Monitoring this expense helps assess the fixed labor costs required to sustain the company's clinical pipeline and scientific innovation.